MLL-AF4 upregulates 5-lipoxygenase expression in t(4;11) leukemia cells via the ALOX5 core promoter [PDF]
Frontiers in Pharmacology5-Lipoxygenase (5-LO), encoded by the gene ALOX5, is implicated in several pathologies. As key enzyme in leukotriene biosynthesis, 5-LO plays a central role in inflammatory diseases, but the 5-LO pathway has also been linked to development of certain ...
Dieter Steinhilber +2 more
exaly +5 more sources
Cell Reports, 2017 Summary: Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic ...
Huimin Geng +2 more
exaly +5 more sources
RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4 [PDF]
Nature Communications, 2022 The establishment of a mouse model of MLL-AF4-induced leukaemia is a challenge as the introduction of fusion gene of human MLL-AF4 does not cause leukaemia in mice.
Hiroshi Okuda +7 more
doaj +3 more sources
MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia [PDF]
Nature Communications, 2023 Aberrant enhancer activation is a key mechanism driving oncogene expression in many cancers. While much is known about the regulation of larger chromosome domains in eukaryotes, the details of enhancer-promoter interactions remain poorly understood ...
Nicholas T. Crump +21 more
doaj +3 more sources
MLL-AF4 and a murinized pSer-variant thereof are turning on the nucleolar stress pathway [PDF]
Cell & Bioscience, 2022 Background Recent pathomolecular studies on the MLL-AF4 fusion protein revealed that the murinized version of MLL-AF4, the MLL-Af4 fusion protein, was able to induce leukemia when expressed in murine or human hematopoietic stem/progenitor cells (Lin et ...
Anna Lena Siemund +3 more
doaj +3 more sources
The human leukemic oncogene MLL-AF4 promotes hyperplastic growth of hematopoietic tissues in Drosophila larvae [PDF]
iScience, 2023 Summary: MLL-rearranged (MLL-r) leukemias are among the leukemic subtypes with poorest survival, and treatment options have barely improved over the last decades.
Julie A. Johannessen +8 more
doaj +3 more sources
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program [PDF]
Nature Communications, 2021 It is unknown why infant acute lymphoblastic leukemia (ALL) produced by MLL rearrangements leads to worse outcomes than childhood ALL. Here the authors develop a CRISPR-Cas9-induced human xenograft model of MLL-AF4 infant-ALL that faithfully replicates ...
Siobhan Rice +19 more
doaj +3 more sources
Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review [PDF]
Frontiers in ImmunologyB-cell acute lymphoblastic leukemia (B-ALL) with the MLL-AF4 fusion gene has a poor prognosis, and the mortality rate exceeds 90%, particularly in cases of extramedullary relapse (EMR).
Xuelian Jin, Zhigang Liu, Yu Wu, Jie Ji
doaj +3 more sources
Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein [PDF]
Scientific Reports, 2021 Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal
Tyler W. Jenkins +8 more
doaj +3 more sources
Concurrent MLL-AF4+ infant ALL in monozygotic twins: a case report [PDF]
Frontiers in PediatricsAcute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, but it is relatively rare in infants. However, infant ALL exhibits distinct biological characteristics and an aggressive course, with a high proportion of cases involving MLL ...
Chenghui Li +4 more
doaj +3 more sources